This article needs additional citations for verification. (October 2023) |
![]() Per capita fully vaccination map as of 4 April 2023 | |
Date | 16 January 2021 (3 years, 215 days ago) | – present
---|---|
Location | ![]() |
Cause | COVID-19 pandemic in India |
Target | Immunisation of Indians against COVID-19 |
Budget | ₹35,000 crore (US$4.2 billion)[1] |
Organised by | Government of India Indian Council of Medical Research State governments of India |
Participants |
|
Outcome |
|
Website | MoHFW |
As on 4th March 2023 (07:00AM) |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
India began administration of COVID-19 vaccines on 16 January 2021. As of 4 March 2023[update], India has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines.[2][3] In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.[4][5]
India initially approved the Oxford–AstraZeneca vaccine (manufactured under license by Serum Institute of India under the trade name Covishield) and Covaxin (a vaccine developed locally by Bharat Biotech). They have since been joined by the Sputnik V (manufactured under license by Dr. Reddy's Laboratories, with additional production from Serum Institute of India being started in September[6][7]), Moderna vaccines, Johnson & Johnson vaccine and ZyCoV-D (a vaccine locally developed by Zydus Cadila)[a][b] and other vaccine candidates undergoing local clinical trials.
According to a June 2022 study published in The Lancet, COVID-19 vaccination in India prevented an additional 4.2 million deaths from December 8, 2020, to December 8, 2021.[8][9]
vaccinate-india
was invoked but never defined (see the help page).
Cite error: There are <ref group=lower-alpha>
tags or {{efn}}
templates on this page, but the references will not show without a {{reflist|group=lower-alpha}}
template or {{notelist}}
template (see the help page).